Floatz logo

AQW051

Drug-induced

Novartis PharmaceuticalsSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Drug-induced cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

AQW051 is also rated in:

schizophreniaDormant
B
Indicative ·
61 / 100
View asset →
drug-induced dyskinesiaDormant
B
Indicative ·
57 / 100
View asset →
Alzheimer diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →